OGE
NYSE · Utilities
Oge Energy Corp
$45.05
-0.46 (-1.01%)
OGE News30 articles
Bitwise Dogecoin ETF Faces Final Trading Day as Closure Looms
BWOW Dogecoin ETF's final trading day is Oct 14; automatic cash redemption follows around Oct 22. Investors face a choice between selling on the market or waiting for liquidation.
Kroger's Q2 Sales Flat, EPS Outlook Steady
Kroger's Q2 sales growth slowed to 0.2%, but EPS beat estimates and full-year guidance was maintained. The company faces challenges from pharmacy headwinds.
Kroger Q2: Can Grocer Defend 1% Sales Floor Amid Buyback Test?
Kroger reports Q2 results Friday with stock at 11x earnings. Key test: same-store sales above 1% and margin stability as $1.8B buyback faces Giant Eagle acquisition.
Rogers Extends Oilers Arena Deal to 2036 Without Disclosing Terms
Rogers Communications locked in its Edmonton Oilers arena naming rights through 2036, but the undisclosed price keeps the deal strategically coherent rather than earnings-changing.
Dogecoin Surges 7.9% Despite Lackluster ETF Demand
Dogecoin rallied 7.9% over the weekend, yet U.S. spot ETFs recorded zero net inflows on Friday, underscoring a disconnect between crypto-native demand and institutional participation.
AbbVie Completes $10.9B Apogee Buyout, Earnings Lift Delayed to 2032
AbbVie finalizes its $10.9B Apogee Therapeutics deal, with earnings accretion not expected until 2032. The acquisition tests investor patience as immunology sales fuel the wait.
AbbVie Completes $10.9B Apogee Buyout, Accretion Delayed to 2032
AbbVie closes its $10.9B Apogee acquisition, projecting EPS dilution until 2032, while strong Skyrizi and Rinvoq growth funds the long-term bet.
Dogecoin's 31% Weekly Surge Puts Coinbase's Revenue Model in Focus
Dogecoin's 31% weekly surge, fueled by U.S. crypto regulation hopes, lifts Coinbase shares 8.2% and tests its revenue diversification strategy.
Rogers Faces Subscriber Growth Concerns After Richmond Fiber Outage
A fiber cut in Richmond, BC has renewed scrutiny on Rogers' network stability as Q2 internet additions fell 35%. Investors watch for impact on churn and retention.
Plug Power's 34% H2 Revenue Hurdle: Can Hydrogen Demand Deliver?
Plug Power shares gained 6.4% to $2.32 after Q2 earnings beat, but the company needs a 34% surge in H2 revenue to meet its 2026 growth target.
Kroger Stock: 137 New Stores Could Offset 60 Closures
Kroger (KR) may add 137 net new stores via the Giant Eagle acquisition, offsetting 60 closures and expanding its footprint by 5.1%.
GAO Audit Casts Doubt on DOGE Savings Claims, Contractors Rally
A GAO audit reveals over half of DOGE's reported contract savings lack proper documentation, yet federal services stocks rise as contractors report strong funded backlogs.
Kroger Egg Recall: Minimal Impact on US Supply, Shares Dip
Midwest Poultry recalls 1.6M dozen eggs sold at Kroger and other retailers, representing 0.25% of US monthly output. No illnesses reported.
Kroger's Pricing Strategy Outshines Walmart in Latest Basket Comparison
Kroger (NYSE:KR) edged out Walmart (NASDAQ:WMT) by 95 cents in a 15-item store-brand basket comparison, showcasing its pricing strategy and margin investments.
Plug Power Shares Slide 5.5% on Target Cut Despite Major Hydrogen Deal
Plug Power shares fell 5.5% Friday after Susquehanna cut its target by $1.25, wiping $1.75 billion in implied equity value, as a 50-MW hydrogen order from Orica failed to calm investor worries about cash flow.
Plug Power Shares Slip Despite 50 MW Electrolyzer Order for Australian Hydrogen Hub
Plug Power shares dropped for a third session despite a major 50 MW electrolyzer order for Australia's largest renewable hydrogen project, as investors focus on cash burn and near-term profitability.
Plug Power Shares Dip on Australian Order Highlighting Hydrogen Subsidy Dependence
Plug Power shares slipped 0.9% after landing a 50 MW electrolyzer order in Australia, where AU$432 million in subsidies highlight the hydrogen market's dependence on government backing.
Kroger's $1.65B Giant Eagle Buy: Low Multiple, High Ambition
Kroger buys Giant Eagle for $1.65 billion, a low 0.18x sales multiple, adding $9 billion in revenue. Deal faces antitrust review but aims to boost margins and EPS by 2027.
AbbVie Surges $17.8 Billion in Market Cap, Surpassing Apogee Deal Value
AbbVie shares soared 3.99% to $261.07, adding $17.8B in market value—more than the $10.9B Apogee deal. The stock now trades above analyst targets, setting up a key Q2 earnings report.
Kroger Acquires Giant Eagle for $1.65B in Targeted Regional Expansion
Kroger has agreed to acquire Giant Eagle for $1.65 billion, a deal valued at just 0.18 times the regional grocer's annual sales, signaling a focused regional strategy.
AbbVie's $65B Surge Outpaces Apogee Acquisition Cost by Sixfold
AbbVie's stock surge added $65B in market cap, six times its $10.9B Apogee deal cost, as Skyrizi approval and immunology demand offset Humira declines.
Kroger's Private Label Scrutiny Rises After USDA Chicken Alert
A USDA alert flagged mislabeled Private Selection chicken at Kroger in nine states, but no adverse reactions were reported. The stock closed Friday at $57.73.
Shuttle Pharma Soars on Dogecoin Mining Entry; Volume Spikes 70x
Shuttle Pharmaceuticals jumped 27% on news its United Dogecoin unit bought miners and secured a hydroelectric site, with volume surging 70x.
Plug Power's Denmark Project Highlights Green Hydrogen Scaling Challenges
Plug Power shares rose 0.4% to $2.62 after completing a 5 MW electrolyzer project in Denmark, which produces less than 4% of its U.S. capacity. The small scale underscores the challenges in hydrogen scaling.
AbbVie Acquires Apogee Therapeutics for $10.9B in Cash, Bolstering Pipeline
AbbVie announced a $10.9 billion cash acquisition of Apogee Therapeutics, adding a promising eczema treatment to its pipeline as it seeks to offset declining Humira sales.
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
Apogee Therapeutics stock jumped 47% after AbbVie agreed to buy the company for $135.11 per share in cash, adding late-stage eczema drug zumilokibart.
AbbVie to Buy Apogee in $10.9B Deal to Boost Immunology Pipeline
AbbVie acquires Apogee Therapeutics for $10.9 billion, paying a 49.49% premium for experimental eczema drug zumilokibart, as it seeks to bolster its immunology franchise.
AbbVie Nears $10.9B Apogee Takeover, Healthcare Stocks in Focus
AbbVie is reportedly close to acquiring Apogee Therapeutics for $10.9 billion in cash, offering a roughly 60% premium. A deal could be announced Monday, putting healthcare stocks in the spotlight.
Plug Power Stock Jumps 7.5% as Tax Credit Sale Boosts Liquidity, Hydrogen Sector Rallies
Plug Power shares jumped 7.55% on Thursday, driven by a $39.2 million tax credit sale and improved gross margins, as the hydrogen sector broadly rallied.
Kroger Shares Dip as Q1 Profit Misses Estimates Despite Revenue Beat
Kroger shares dropped 3% premarket after Q1 adjusted profit missed estimates by a cent, despite a sales beat. Margin pressure from price cuts and transport costs raised investor doubts.